









# IKNOW YOU...

...are in love with my glistening free<sup>2,3</sup> material

...are in love with my resistance to tough conditions<sup>4</sup>

...are in love with my rotational and refractive stability<sup>2, 3, 5, 6</sup>

...are in love with my low PCO\* rate<sup>2,7</sup>



#### \*PCO: Posterior Capsular Opacification

3. P. Heiner et al. 'Safety and effectiveness of a single-piece hydrophobic acrylic intraocular lens' (en Vista®) - results of a European and Asian-Pacific study. Clinical Ophthalmology 2014:8 629-635.
4. BAUSCH+LOMB data on file: rb\_011216\_081636\_Enhanced en Vista\_Material Properties Testing

For et al. Prospective multicenter clinical trial to evaluate the safety and effectiveness of a new glistening-free one-piece acrylic toric intraocular lens. Clinical Ophthalmology 2018:12 1031-103. zón N et al. Evaluation of Rotation and Visual Outcomes After Implantation of Monofocal and Multifocal Toric Intraocular Lenses. J. Refract. Surg., 2015:31(2), 1-9. Van C., Tran THC. Incidence of posterior capsular opacification requiring Nd:YAG capsulotomy after cataract surgery and implantation of enVista® MX60 IOL. J Fr Ophtalmol. 2018 Dec;41(10):899-903

CATARACT









# BUT ALSO I KNOW...

...that sometimes you flirt with others with **quicker unfolding** than me, maybe lam a little bit shy

...you are looking for an easy solution, as a **preloaded** relationship

I promise that from now on, I will give you what you are looking for...








## GLISTENING-FREE MATERIAL

## Trusight<sup>TM</sup> Optic - Glistening-free

Hydration to an equilibrium water content and then packaged in 0.9 % physiologic saline solution to prevent glistening formation

No glistenings of any grade were reported for any subject at any visit<sup>8,9</sup>



dry state

equilibrium wet state

#### Accelerated ageing in-vitro glistening evaluation 10

IOL	Average Microvacuoles/mm²± Standard Deviation
Enhanced enVista®	0.59 ± 0.63
Clareon® IOL (Alcon)	1.20 ± 1.16
MicroPure (PhysIOL)	2.45 ± 3.13

## **COMPRESSION FORCES**

Accuset<sup>TM</sup> Haptics - designed for refractive predictability and stable centration<sup>8, 9, 11</sup>



ISO 11979-3 model

Large capsular bag contact

- **▶** Fenestrated haptics to prevent transfer of stress from the haptic to the optic
- ▶ Haptics designed to maximize the contact angle against the capsular bag



enVista® IOL 12 (Based on 10 mm capsular bag)



AcrySof IQ®13 (Based on 10 mm capsular bag)



Tecnis IOL® 14 (Based on 10 mm capsular bag)

<sup>11.</sup> Garzon et al., Evaluation of Visual Outcomes After Implantation of Monofocal and Multifocal Toric Intraocular Lenses. J Refract Surg. 2015;31(2):90-97.

12. BAUSCH + LOMB data on file: Intraocular lens design verification report- July 2016.

13. BAUSCH + LOMB data on file: IOL competitive benchmarking study report\_DEC 2009.

14. PMA P980040/S039: FDA Summary of Safety and Effectiveness Data\_Tecnis Toric IOL.



# FASTER UNFOLDING

## Stableflex<sup>TM</sup> Technology

Ò

#### Formulation updated for faster unfolding


The Enhanced enVista® IOL material is made of the same polymers as its precursor, but their proportions have been modified to decrease the glass transition temperature (Tg) from 23°C to 15°C

The lower Tg of the Enhanced enVista® allows better injectability, with faster and improved unfolding efficiency at lower temperatures (18°C to 30°C) compared to the enVista®.

# +20.00 D Unfolding at 25°C enVista® Enhanced enVista®

Images comparing the unfolding time between enVista® and Enhanced enVista®15

#### Unfolding time according to temperature (laboratory testing)<sup>15</sup>



Scan here to watch a video of the faster unfolding with the Enhanced en Vista®





# ABERRATION-FREE ASPHERIC OPTIC DESIGN

Enhanced en Vista® is designed to have no spherical aberrations. It is inherently "aberration-free". The resultant pseudophakic eye has a natural amount of positive spherical aberration.

Residual spherical aberration = Natural positive spherical aberration of the phakic eye with Enhanced en Vista®

Average:  $+0.274 \pm 0.089 \, \mu m^{16}$ 



#### Depth of focus and residual spherical aberration

Maintaining a certain amount of positive spherical aberration after surgery can provide greater depth of focus<sup>17</sup>

Many authors indicate that it is beneficial for vision quality to maintain residual spherical aberration<sup>18</sup>





The depth of focus should be greater with an aspherical IOL that does not induce aberration, in comparison with an aspheric IOL that induces negative aberration. Some studies found that the depth of focus was significantly greater<sup>20,21</sup>

#### Simulation of visual acuity with depth of focus -0.50 D Emmetropia 0.50 D 0.575D 20/50 Simulation of eye with an aberration 20/40 free IOL 20/30 20/20 20/10 20/50 Simulation of eye with a negative 20/40 spherical 20/30 aberration IOL

USAF resolution test chart obtained by R+D laboratory testing at BAUSCH +  $LOMB^{22}$ 

- Using optical ray tracing simulations, the aberration free IOL demonstrated a wider range of improved image resolution when compared to a negative spherical aberration IOL.
- Aberration-free IOL shows a 0.25 D to 0.30 D depth of focus increase based on the resolvability of the target of 20/20 or 20/30.


	Depth of focus based on 20/20 vision	Depth of focus based on 20/30 vision		
Aberration free IOL	-0.5 D to +0.25 D, total 0.75 D	-0.75D to +0.375 D, total 1.125 D		

Data obtained by R+D laboratory testing at BAUSCH + LOMB<sup>22</sup>

20/20







A multicentre study has shown that aspheric optics with Advanced Optics technology provide greater depth of field than aspheric optics with negative aberration, which could contribute to greater visual quality perception<sup>23</sup>

Nomogram for targeting refractive error to balance residual spherical aberration after adjusting for pupil size when implanting an aberration-free IOL<sup>24</sup>

	Corneal spherical aberration (at 6.0 mm)	0.07 µm	<b>0.17</b> µm	<b>0.27</b> µm	0.37 µm	0.47 µm
	6 mm					
	5.5 mm					
Pupil Size	5 mm					
	4.5 mm					
	4 mm					
	3.5 mm					
	3 mm					
1				一		

plano

-0.25 D

-0.50 D

Balance against post-op modest hyperopic refraction




#### Tolerance to decentration


Decentration is much more frequent than one might think

In general, the average decentration after uncomplicated cataract surgery reported in studies is  $0.30 \pm 0.16$  mm (Range 0 to 1.9 mm)<sup>25</sup>

- The neutral aspherical design of both the anterior and posterior optical surfaces of the Enhanced enVista<sup>®</sup> lens allows for the constant power of the lens, from the centre to the periphery of its optic
- Enhanced enVista<sup>®</sup> lens is aberration-free and, therefore, it does not induce other aberrations in case of decentration, even with decentration of 1 mm of more<sup>25</sup>



### Performance of different IOLs based on decentration<sup>26</sup>



**A.** The IOLs are decentered 0.5 mm. Induction of asymmetrical HOAs degraded the performances of both the spherical IOL and the one inducing negative spherical aberration, causing the MTF curves to droop and separate.

**B.** The IOLs are decentered 1.0 mm, further degrading performance of the spherical IOL and the one inducing negative spherical aberration IOL but not the aberration-free IOL.

Figure adapted from Altman GE, et al. 2005. Sensitivity to contrast in mesopic conditions ( $3 \text{ cd/m}^2$ ) in patients with Akreos® AO (pupils  $4.01 \pm 0.45 \text{mm}$ ) and Akreos® spherical Fit (pupil  $4.04 \pm 0.41 \text{mm}$ )<sup>26</sup>
\*MTF: Modulation Transference Function







## 360° POSTERIOR OPTIC BARRIER

#### SureEdge<sup>TM</sup> Design - Continuous 360° posterior square edge

Implantation of the en Vista $^{\text{@}}$  (MX60P) is associated with low, three-year cumulative incidence rates of PCO requiring Nd:YAG laser capsulotomy.



A- Square edge continues at optic haptic junction.




B- Edge profile. Radius of curvature <10 µm.



C- Edge profile at Optic-haptic junction. Radius of curvature <10 µm.

All images of +20.00 D IOLs shown at same scale to aid comparison. Posterior optic edge at top left of all images. By courtesy of D. Spalton<sup>27</sup>




# SCRATCH RESISTANCE<sup>29</sup>

#### Nonoscratch Evaluation done by R+D laboratory testing at BAUSCH + LOMB:

Ramped load scratches were generated in 0.3-80 mN range using a 8 micron radius, 60 degree conical diamond stylus while submerged in saline solution.

- Scratch velocity of 5 mm/minute and a loading rate of 199.25 mN/minute.
- Optical microscope to examine scratch morphologies and determine the onset of cracking/material damage.





# PRELOADED IOL

en Vista® preloaded with the BAUSCH + LOMB SimplifEYE™ delivery system.

- Less risk of IOL damage, cross-contamination and mishandling.<sup>30</sup>
- It is thought that during the next several years, the use of preloaded IOLs is expected to **grow** and may well represent the **industry's** future<sup>31</sup>








## CLINICAL EXPERIENCES SINCE 2010 THE OUTCOMES ARE CLEAR

Aberration-free optic | Glistening-free performance | Predictable outcomes

More than 3 million of implantations since 2013



*Constants	are	estimates	only.	lt	is	recommended	that	each	surgeon
develops the	eir ov	wn							

Optic design	Aspheric, aberration-free, biconvex
Optic diameter	6.00 mm
Overall diameter	12.50 mm
Haptics	Modified C-loop, fenestrated, Step Vaulted
Optic constant	SRK/T Constant A: 119.1 ACD: 5.61 Surgeon factor: 1.85 Haigis: a <sub>0</sub> : 1.46 / a <sub>1</sub> : 0.40 / a <sub>2</sub> : 0.10
Ultrasonic constant	Constant A: 118.7 ACD: 5.37 Surgeon factor: 1.62
Other features	Glistening-free hydrophobic acrylic material Abbe number: 42 Refractive index: 1.53 at 35°C UV absorbing Sharp 360° posterior square edge
Diopter range	From 0.00 D to +10.00 D (1.00 D steps) From +10.00 D to +30.00 D (0.50 D steps) From +30.00 D to +34.00 D (1.00 D steps
Delivery system	$BAUSCH + LOMB \ SimplifEYE^{TM} \ delivery \ system \\ Recommended \ incision \ size \geq 2.2 \ mm$



@BauschSurgical



in Bausch + Lomb Surgical

www.bauschsurgical.eu

© 2020 Bausch + Lomb Incorporated. All rights reserved.  $^{\circ}/^{\text{IM}}$  are trademarks of Bausch & Lomb Incorporated or its affiliates All other brand/product names are trademarks of the respective owners. EMEA\_SU\_B\_ENVISTAS\_20\_001







